Skip to content
Sunday 9 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,901.09
+0.31%
DAX
26,319.45
+0.69%
CAC 40
8,714.93
+0.17%
STOXX 50
6,523.86
+0.33%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Monday 29 June 2026 3:19 pm  |  Updated:  Monday 29 June 2026 4:09 pm

Medisca Enters Its Next Chapter Under Founder Antonio Dos Santos

By: Business Wire

Add as a preferred source on Google

For more than 35 years, Dos Santos has helped shape Medisca into a global leader in pharmaceutical compounding. As Chief Executive Officer, he will lead the company’s long-term strategy, with a focus on expanding Medisca’s global reach, investing in new areas of growth, strengthening strategic partnerships, and continuing to advance the products, services, education, and expertise that healthcare professionals rely on every day.

“When I founded Medisca, my vision was to raise the standard of pharmaceutical compounding by bringing pharmaceutical-grade quality to the industry and giving healthcare professionals access to the products, knowledge, and innovation they needed to deliver better patient care,” said Antonio Dos Santos, Founder and Chief Executive Officer of Medisca. “That purpose continues to guide us. As we begin this next chapter, we’ll keep investing in our people, our partnerships, and the innovation that will help shape the future of Medisca and the pharmaceutical compounding industry.”

Working alongside Vice-Chair Maria Zaccardo and Medisca’s C-Suite, Dos Santos will continue to guide the company’s strategic direction as Medisca continues to expand globally and invest in its long-term growth.

“For over three decades, Medisca has grown by staying true to its purpose while continuing to evolve with the needs of healthcare professionals,” said Maria Zaccardo, Vice-Chair of Medisca. “As we look ahead, we remain focused on supporting our customers, investing in our people, and continuing to strengthen Medisca for the future.”

As part of this leadership transition, Sanjay Goorachurn has stepped down from his role as Chief Executive Officer. Medisca thanks Sanjay for his dedication and contributions to the organization and wishes him continued success.

As Medisca continues to grow globally, the company remains committed to empowering personalized wellness for all by expanding the products, technologies, education, and expertise that help healthcare professionals deliver better patient care around the world.

About Medisca

Founded in 1989, Medisca is a leader in personalized medicine and pharmaceutical supply chain solutions, with a vast portfolio of over 2,000 products completed by a library of 10,000+ proprietary and customized medication formulas, expertise and services in pharmaceutical compounding, continuing healthcare education, and analytical testing. Providing finely-tuned solutions to diverse wellness sectors in numerous markets globally, Medisca is bridging the gaps in healthcare and empowering personalized wellness for all. For more information, visit www.Medisca.com and follow us on LinkedIn, Facebook, and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260629786213/en/

Contact

Medisca Communications
[email protected]
1-800-665-6334

TweetText

As Medisca enters its next chapter, we remain committed to raising the standard of pharmaceutical compounding and supporting healthcare professionals with the products, knowledge, and innovation they need to deliver better patient care.

Company Logo
Company Logo
Read more

Clinigen Appoints Greg Skalicky as Chief Executive Officer

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Businesswire

Categories

  • Personnel

Trending Articles

  • Thames Water faces fresh threat to survival after pensions regulation breach

  • PwC’s Embankment HQ to get major makeover ahead of Canary Wharf move

  • Family feud: London estate agent Winkworth sues chair over plot with wife to oust son from board

  • As it happened: Stocks rise despite new tensions in Strait of Hormuz; Oil price climbs

  • A tribute to wine legend Matthew Jukes by his friend Libby Brodie

More from Morning Wire

  • Clinigen Appoints Greg Skalicky as Chief Executive Officer

    Business Wire
  • Tenpoint Therapeutics Announces United Kingdom Submission of Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults

    Business Wire
  • Patent cliff fuels Novartis’ $1.5bn swoop for London biotech

    Healthcare
    Hikma produces generic drugs
  • NADclinic and GCLS Announce Strategic Collaboration in Longevity and Performance Medicine Education

    Business Wire
  • ICON announces multi-year collaboration with Anthropic to bring frontier AI to clinical trials

    Business Wire
  • QX Global Group Appoints Vijay Pahuja as Group Chief Executive Officer

    Business Wire
  • Real Chemistry Launches Real Chemistry ANATOMI, an AI Ecosystem Purpose-Built for Healthcare Commercialization

    Business Wire
  • Vodafone pushes into legal tech market to co-develop AI platform

    Legal
    Vodafone Group has announced the appointment of Microsoft's Pilar López as its new chief financial officer.
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook